|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
0.60/0.10
|
企业价值
3.27B
|
资产负债 |
每股账面净值
4.28
|
现金流量 |
现金流量率
0.07
|
损益表 |
收益
838.00M
|
每股收益
4.44
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/06/02 07:14 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |